| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 5 | 2025 | 10 | 3.280 |
Why?
|
| Fibroblasts | 4 | 2025 | 16 | 3.050 |
Why?
|
| Brachyura | 3 | 2024 | 9 | 2.110 |
Why?
|
| Liver Cirrhosis | 3 | 2024 | 11 | 2.090 |
Why?
|
| Animals | 27 | 2025 | 1817 | 1.990 |
Why?
|
| Glycoside Hydrolase Inhibitors | 2 | 2024 | 2 | 1.880 |
Why?
|
| Skin | 2 | 2024 | 29 | 1.830 |
Why?
|
| Mice | 19 | 2025 | 719 | 1.730 |
Why?
|
| Humans | 39 | 2025 | 5485 | 1.690 |
Why?
|
| Apoptosis | 4 | 2025 | 55 | 1.440 |
Why?
|
| Male | 25 | 2025 | 2770 | 1.440 |
Why?
|
| Female | 25 | 2025 | 2816 | 1.430 |
Why?
|
| Signal Transduction | 7 | 2025 | 225 | 1.430 |
Why?
|
| Antioxidants | 3 | 2025 | 27 | 1.400 |
Why?
|
| MAP Kinase Signaling System | 2 | 2025 | 8 | 1.210 |
Why?
|
| alpha-Glucosidases | 2 | 2024 | 2 | 1.190 |
Why?
|
| NF-kappa B | 2 | 2025 | 11 | 1.190 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 2 | 2024 | 2 | 1.180 |
Why?
|
| Fermentation | 2 | 2024 | 4 | 1.170 |
Why?
|
| Single-Cell Analysis | 2 | 2025 | 24 | 1.170 |
Why?
|
| Macrophages | 2 | 2025 | 29 | 1.170 |
Why?
|
| Reactive Oxygen Species | 2 | 2024 | 35 | 1.170 |
Why?
|
| Molecular Docking Simulation | 2 | 2025 | 30 | 1.150 |
Why?
|
| DNA Methylation | 2 | 2024 | 30 | 1.150 |
Why?
|
| Phylogeny | 2 | 2024 | 66 | 1.150 |
Why?
|
| Cell Movement | 2 | 2024 | 64 | 1.140 |
Why?
|
| Peptides | 2 | 2024 | 51 | 1.120 |
Why?
|
| Mice, Inbred C57BL | 7 | 2025 | 195 | 1.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2025 | 5 | 1.030 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2025 | 34 | 1.000 |
Why?
|
| Fatty Liver | 2 | 2024 | 8 | 0.990 |
Why?
|
| Transcription Activator-Like Effector Nucleases | 1 | 2025 | 1 | 0.970 |
Why?
|
| Proviruses | 1 | 2025 | 1 | 0.970 |
Why?
|
| HIV-1 | 1 | 2025 | 1 | 0.970 |
Why?
|
| Apigenin | 1 | 2025 | 2 | 0.970 |
Why?
|
| Reperfusion Injury | 1 | 2025 | 4 | 0.970 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2025 | 3 | 0.960 |
Why?
|
| Glycoproteins | 1 | 2025 | 3 | 0.960 |
Why?
|
| Thiostrepton | 1 | 2024 | 1 | 0.960 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2025 | 12 | 0.960 |
Why?
|
| Ecdysterone | 1 | 2024 | 1 | 0.960 |
Why?
|
| Cervix Mucus | 1 | 2024 | 1 | 0.960 |
Why?
|
| Forensic Genetics | 1 | 2024 | 1 | 0.960 |
Why?
|
| CpG Islands | 1 | 2024 | 6 | 0.950 |
Why?
|
| Artemisia | 1 | 2024 | 1 | 0.950 |
Why?
|
| Methoprene | 1 | 2024 | 2 | 0.950 |
Why?
|
| Metamorphosis, Biological | 1 | 2024 | 2 | 0.950 |
Why?
|
| alpha-Amylases | 1 | 2024 | 3 | 0.950 |
Why?
|
| Semen | 1 | 2024 | 3 | 0.950 |
Why?
|
| Chemokine CXCL1 | 1 | 2024 | 1 | 0.950 |
Why?
|
| Oxysterols | 1 | 2024 | 2 | 0.950 |
Why?
|
| Intestinal Mucosa | 1 | 2025 | 27 | 0.950 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2024 | 13 | 0.950 |
Why?
|
| Hepatic Encephalopathy | 1 | 2024 | 3 | 0.950 |
Why?
|
| Larva | 1 | 2024 | 12 | 0.950 |
Why?
|
| Salmonella typhimurium | 4 | 2025 | 4 | 0.950 |
Why?
|
| Interleukin-1beta | 1 | 2024 | 18 | 0.940 |
Why?
|
| Vaccines, Subunit | 1 | 2024 | 1 | 0.940 |
Why?
|
| Collagen Type VI | 1 | 2024 | 1 | 0.940 |
Why?
|
| Calcium Hydroxide | 1 | 2024 | 1 | 0.940 |
Why?
|
| Sequence Analysis, DNA | 1 | 2024 | 27 | 0.940 |
Why?
|
| Neutrophils | 1 | 2024 | 19 | 0.940 |
Why?
|
| Apolipoproteins E | 1 | 2024 | 5 | 0.940 |
Why?
|
| Colorectal Neoplasms | 1 | 2024 | 14 | 0.940 |
Why?
|
| Tea | 1 | 2024 | 1 | 0.940 |
Why?
|
| Saliva | 1 | 2024 | 20 | 0.930 |
Why?
|
| Lipid Metabolism | 1 | 2024 | 14 | 0.930 |
Why?
|
| Flavonoids | 1 | 2024 | 22 | 0.930 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 15 | 0.920 |
Why?
|
| Atherosclerosis | 1 | 2024 | 16 | 0.910 |
Why?
|
| Machine Learning | 1 | 2024 | 39 | 0.910 |
Why?
|
| Sleep Wake Disorders | 1 | 2024 | 30 | 0.900 |
Why?
|
| Anti-Bacterial Agents | 2 | 2024 | 183 | 0.820 |
Why?
|
| Disease Models, Animal | 10 | 2025 | 242 | 0.820 |
Why?
|
| Mice, Nude | 4 | 2025 | 24 | 0.760 |
Why?
|
| Adult | 11 | 2025 | 1687 | 0.730 |
Why?
|
| Middle Aged | 8 | 2024 | 1100 | 0.710 |
Why?
|
| Postoperative Complications | 3 | 2025 | 17 | 0.710 |
Why?
|
| Fibrosarcoma | 3 | 2025 | 3 | 0.710 |
Why?
|
| Risk Factors | 6 | 2025 | 184 | 0.660 |
Why?
|
| Breast Neoplasms | 3 | 2025 | 107 | 0.620 |
Why?
|
| Cell Line, Tumor | 8 | 2025 | 175 | 0.610 |
Why?
|
| Incidence | 4 | 2025 | 33 | 0.590 |
Why?
|
| Cells, Cultured | 4 | 2025 | 134 | 0.570 |
Why?
|
| Aged | 6 | 2025 | 860 | 0.530 |
Why?
|
| Transcriptome | 3 | 2025 | 47 | 0.520 |
Why?
|
| Mice, Knockout | 3 | 2024 | 143 | 0.500 |
Why?
|
| Esophageal Neoplasms | 2 | 2025 | 6 | 0.480 |
Why?
|
| Cell Communication | 2 | 2025 | 16 | 0.470 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2024 | 14 | 0.460 |
Why?
|
| Green Fluorescent Proteins | 2 | 2025 | 24 | 0.460 |
Why?
|
| Epigenesis, Genetic | 2 | 2024 | 31 | 0.460 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2024 | 41 | 0.460 |
Why?
|
| China | 4 | 2024 | 28 | 0.410 |
Why?
|
| Retrospective Studies | 5 | 2025 | 382 | 0.410 |
Why?
|
| Disease Progression | 3 | 2024 | 74 | 0.350 |
Why?
|
| Global Burden of Disease | 2 | 2025 | 2 | 0.300 |
Why?
|
| RAW 264.7 Cells | 2 | 2025 | 6 | 0.300 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2025 | 5 | 0.300 |
Why?
|
| Pregnancy Rate | 2 | 2024 | 3 | 0.300 |
Why?
|
| Polysaccharides | 2 | 2024 | 3 | 0.300 |
Why?
|
| Biomarkers, Tumor | 2 | 2025 | 19 | 0.300 |
Why?
|
| Dendritic Cells | 2 | 2024 | 10 | 0.300 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2025 | 15 | 0.300 |
Why?
|
| Plant Extracts | 2 | 2024 | 20 | 0.290 |
Why?
|
| Prognosis | 2 | 2024 | 59 | 0.290 |
Why?
|
| Transcription Factors | 2 | 2025 | 69 | 0.280 |
Why?
|
| T-Lymphocytes | 2 | 2025 | 48 | 0.280 |
Why?
|
| Cell Differentiation | 2 | 2025 | 75 | 0.280 |
Why?
|
| Antineoplastic Agents | 2 | 2025 | 72 | 0.270 |
Why?
|
| Virus Replication | 1 | 2025 | 2 | 0.240 |
Why?
|
| Doxorubicin | 1 | 2025 | 6 | 0.240 |
Why?
|
| RNA, Catalytic | 1 | 2025 | 2 | 0.240 |
Why?
|
| Antigen-Presenting Cells | 1 | 2025 | 1 | 0.240 |
Why?
|
| Immunomodulation | 1 | 2025 | 1 | 0.240 |
Why?
|
| Immunoconjugates | 1 | 2025 | 1 | 0.240 |
Why?
|
| 1-Acylglycerophosphocholine O-Acyltransferase | 1 | 2025 | 1 | 0.240 |
Why?
|
| Lysophosphatidylcholines | 1 | 2025 | 1 | 0.240 |
Why?
|
| Nanocapsules | 1 | 2025 | 1 | 0.240 |
Why?
|
| Oligodendroglia | 1 | 2025 | 2 | 0.240 |
Why?
|
| Ankle Fractures | 1 | 2025 | 1 | 0.240 |
Why?
|
| Antigen Presentation | 1 | 2025 | 7 | 0.240 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2025 | 1 | 0.240 |
Why?
|
| Frailty | 1 | 2025 | 2 | 0.240 |
Why?
|
| Myelin Sheath | 1 | 2025 | 4 | 0.240 |
Why?
|
| Cell Adhesion Molecules | 1 | 2025 | 6 | 0.240 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2025 | 1 | 0.240 |
Why?
|
| Selenium | 1 | 2025 | 3 | 0.240 |
Why?
|
| Cucurbitaceae | 1 | 2025 | 1 | 0.240 |
Why?
|
| Cellular Microenvironment | 1 | 2025 | 2 | 0.240 |
Why?
|
| Phosphatidylcholines | 1 | 2025 | 3 | 0.240 |
Why?
|
| Macrophage Activation | 1 | 2025 | 2 | 0.240 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2025 | 5 | 0.240 |
Why?
|
| Cyprinidae | 1 | 2025 | 3 | 0.240 |
Why?
|
| Carbon-Sulfur Lyases | 1 | 2025 | 1 | 0.240 |
Why?
|
| Metabolome | 1 | 2025 | 6 | 0.240 |
Why?
|
| Phagocytosis | 1 | 2025 | 6 | 0.240 |
Why?
|
| HCT116 Cells | 1 | 2024 | 2 | 0.240 |
Why?
|
| Methionine | 1 | 2025 | 3 | 0.240 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2024 | 2 | 0.240 |
Why?
|
| Stomach Neoplasms | 1 | 2025 | 5 | 0.240 |
Why?
|
| Materials Testing | 1 | 2025 | 19 | 0.240 |
Why?
|
| Fertilization in Vitro | 1 | 2024 | 3 | 0.240 |
Why?
|
| Cryopreservation | 1 | 2024 | 3 | 0.240 |
Why?
|
| Menstruation | 1 | 2024 | 1 | 0.240 |
Why?
|
| Osteoarthritis | 1 | 2025 | 6 | 0.240 |
Why?
|
| Antigens, Neoplasm | 1 | 2025 | 9 | 0.240 |
Why?
|
| Keratinocytes | 1 | 2024 | 1 | 0.240 |
Why?
|
| Spermatozoa | 1 | 2024 | 5 | 0.240 |
Why?
|
| Pregnancy Outcome | 1 | 2024 | 6 | 0.240 |
Why?
|
| PPAR gamma | 1 | 2024 | 2 | 0.240 |
Why?
|
| Freezing | 1 | 2024 | 4 | 0.240 |
Why?
|
| Blood Chemical Analysis | 1 | 2024 | 4 | 0.240 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2024 | 1 | 0.240 |
Why?
|
| Arthropod Proteins | 1 | 2024 | 1 | 0.240 |
Why?
|
| Picrates | 1 | 2024 | 1 | 0.240 |
Why?
|
| Sulfonic Acids | 1 | 2024 | 1 | 0.240 |
Why?
|
| Benzothiazoles | 1 | 2024 | 3 | 0.240 |
Why?
|
| Chloroquine | 1 | 2025 | 10 | 0.240 |
Why?
|
| Camptothecin | 1 | 2025 | 10 | 0.240 |
Why?
|
| Mice, Inbred BALB C | 1 | 2024 | 22 | 0.240 |
Why?
|
| Seaweed | 1 | 2024 | 1 | 0.240 |
Why?
|
| Fucus | 1 | 2024 | 1 | 0.240 |
Why?
|
| Cardiotoxicity | 1 | 2024 | 1 | 0.240 |
Why?
|
| Alginates | 1 | 2024 | 2 | 0.240 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2024 | 10 | 0.240 |
Why?
|
| Juvenile Hormones | 1 | 2024 | 3 | 0.240 |
Why?
|
| Body Fluids | 1 | 2024 | 5 | 0.240 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2024 | 3 | 0.240 |
Why?
|
| Serum Amyloid A Protein | 1 | 2024 | 1 | 0.240 |
Why?
|
| Precision Medicine | 1 | 2025 | 14 | 0.240 |
Why?
|
| Biphenyl Compounds | 1 | 2024 | 8 | 0.240 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2024 | 6 | 0.240 |
Why?
|
| Pharmacovigilance | 1 | 2024 | 2 | 0.240 |
Why?
|
| Capillary Leak Syndrome | 1 | 2024 | 1 | 0.240 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2024 | 2 | 0.240 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 2024 | 1 | 0.240 |
Why?
|
| Intracranial Aneurysm | 1 | 2024 | 2 | 0.240 |
Why?
|
| Orexins | 1 | 2024 | 1 | 0.240 |
Why?
|
| Melanoma, Experimental | 1 | 2024 | 4 | 0.240 |
Why?
|
| Extracellular Traps | 1 | 2024 | 3 | 0.240 |
Why?
|
| Cytochrome P450 Family 7 | 1 | 2024 | 1 | 0.240 |
Why?
|
| Steroid Hydroxylases | 1 | 2024 | 1 | 0.240 |
Why?
|
| Capillary Permeability | 1 | 2024 | 4 | 0.240 |
Why?
|
| Myocardial Infarction | 1 | 2024 | 11 | 0.240 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2024 | 1 | 0.240 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2024 | 1 | 0.240 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2024 | 1 | 0.240 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2024 | 1 | 0.240 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2024 | 2 | 0.240 |
Why?
|
| Drug Delivery Systems | 1 | 2025 | 27 | 0.240 |
Why?
|
| Diabetic Retinopathy | 1 | 2025 | 11 | 0.240 |
Why?
|
| Optical Imaging | 1 | 2025 | 18 | 0.240 |
Why?
|
| Ependyma | 1 | 2024 | 1 | 0.240 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2024 | 1 | 0.240 |
Why?
|
| Carrier State | 1 | 2024 | 2 | 0.240 |
Why?
|
| Genetic Markers | 1 | 2024 | 10 | 0.240 |
Why?
|
| RGS Proteins | 1 | 2024 | 3 | 0.240 |
Why?
|
| Panax notoginseng | 1 | 2024 | 1 | 0.240 |
Why?
|
| Particle Size | 1 | 2025 | 43 | 0.240 |
Why?
|
| Saponins | 1 | 2024 | 4 | 0.240 |
Why?
|
| Th1 Cells | 1 | 2024 | 1 | 0.240 |
Why?
|
| Conservation of Natural Resources | 1 | 2024 | 4 | 0.240 |
Why?
|
| Plant Leaves | 1 | 2024 | 4 | 0.240 |
Why?
|
| Freeze Drying | 1 | 2024 | 3 | 0.240 |
Why?
|
| Acute Kidney Injury | 1 | 2025 | 15 | 0.240 |
Why?
|
| Calcium Compounds | 1 | 2024 | 2 | 0.240 |
Why?
|
| Cilia | 1 | 2024 | 7 | 0.240 |
Why?
|
| Plant Stems | 1 | 2024 | 3 | 0.240 |
Why?
|
| Biocompatible Materials | 1 | 2025 | 23 | 0.240 |
Why?
|
| Respiratory Tract Infections | 1 | 2024 | 5 | 0.240 |
Why?
|
| Sarcopenia | 1 | 2024 | 2 | 0.240 |
Why?
|
| Sulfur | 1 | 2024 | 5 | 0.240 |
Why?
|
| Oxides | 1 | 2024 | 6 | 0.240 |
Why?
|
| Drug Compounding | 1 | 2024 | 4 | 0.240 |
Why?
|
| Coinfection | 1 | 2024 | 4 | 0.240 |
Why?
|
| Environmental Monitoring | 1 | 2024 | 10 | 0.240 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2024 | 1 | 0.230 |
Why?
|
| Immunity | 1 | 2024 | 9 | 0.230 |
Why?
|
| Cell Line | 1 | 2025 | 86 | 0.230 |
Why?
|
| Head and Neck Neoplasms | 1 | 2024 | 3 | 0.230 |
Why?
|
| Cytokines | 1 | 2025 | 37 | 0.230 |
Why?
|
| Databases, Factual | 1 | 2024 | 32 | 0.230 |
Why?
|
| Proportional Hazards Models | 1 | 2024 | 30 | 0.230 |
Why?
|
| beta-Lactamases | 1 | 2024 | 13 | 0.230 |
Why?
|
| Hep G2 Cells | 1 | 2024 | 6 | 0.230 |
Why?
|
| Amino Acid Sequence | 1 | 2024 | 54 | 0.230 |
Why?
|
| Embryonic Development | 1 | 2024 | 14 | 0.230 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 20 | 0.230 |
Why?
|
| Enzyme Inhibitors | 1 | 2024 | 34 | 0.230 |
Why?
|
| Bibliometrics | 1 | 2024 | 9 | 0.230 |
Why?
|
| Embryo, Nonmammalian | 1 | 2024 | 19 | 0.230 |
Why?
|
| Autophagy | 1 | 2025 | 31 | 0.230 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2024 | 9 | 0.230 |
Why?
|
| Insulin Resistance | 1 | 2024 | 9 | 0.230 |
Why?
|
| Adsorption | 1 | 2024 | 46 | 0.230 |
Why?
|
| Hydrocephalus | 1 | 2024 | 18 | 0.230 |
Why?
|
| Life Change Events | 1 | 2024 | 19 | 0.230 |
Why?
|
| Asthenozoospermia | 1 | 2024 | 1 | 0.230 |
Why?
|
| Sperm Motility | 1 | 2024 | 3 | 0.230 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 26 | 0.230 |
Why?
|
| Immunotherapy | 1 | 2024 | 22 | 0.230 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 26 | 0.230 |
Why?
|
| Liver | 1 | 2025 | 51 | 0.230 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2024 | 20 | 0.230 |
Why?
|
| Kidney | 1 | 2025 | 53 | 0.230 |
Why?
|
| Catalysis | 1 | 2024 | 63 | 0.230 |
Why?
|
| Diet, High-Fat | 1 | 2024 | 35 | 0.230 |
Why?
|
| Inflammation | 1 | 2024 | 59 | 0.230 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2024 | 33 | 0.230 |
Why?
|
| Oxidative Stress | 1 | 2025 | 59 | 0.230 |
Why?
|
| Prospective Studies | 1 | 2024 | 132 | 0.230 |
Why?
|
| Killer Cells, Natural | 1 | 2024 | 33 | 0.230 |
Why?
|
| Cohort Studies | 1 | 2024 | 131 | 0.230 |
Why?
|
| Ecosystem | 1 | 2024 | 59 | 0.220 |
Why?
|
| Evolution, Molecular | 1 | 2024 | 68 | 0.220 |
Why?
|
| Nanoparticles | 1 | 2025 | 74 | 0.220 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2024 | 68 | 0.220 |
Why?
|
| Quality of Life | 1 | 2024 | 117 | 0.210 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2024 | 63 | 0.210 |
Why?
|
| Aging | 1 | 2024 | 127 | 0.210 |
Why?
|
| Students | 1 | 2024 | 122 | 0.200 |
Why?
|
| Depression | 1 | 2024 | 133 | 0.200 |
Why?
|
| Algorithms | 1 | 2024 | 275 | 0.200 |
Why?
|
| Exercise | 1 | 2024 | 176 | 0.190 |
Why?
|
| Young Adult | 4 | 2025 | 852 | 0.170 |
Why?
|
| Adolescent | 3 | 2024 | 806 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2024 | 15 | 0.120 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 97 | 0.120 |
Why?
|
| Administration, Oral | 2 | 2025 | 35 | 0.110 |
Why?
|
| Cell Proliferation | 2 | 2025 | 120 | 0.110 |
Why?
|
| Pregnancy | 2 | 2024 | 103 | 0.110 |
Why?
|
| Mutation | 2 | 2025 | 137 | 0.110 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 321 | 0.110 |
Why?
|
| Neoplasms | 2 | 2025 | 99 | 0.100 |
Why?
|
| Nucleocapsid | 1 | 2025 | 1 | 0.060 |
Why?
|
| Nucleocapsid Proteins | 1 | 2025 | 1 | 0.060 |
Why?
|
| Vero Cells | 1 | 2025 | 4 | 0.060 |
Why?
|
| Genome, Viral | 1 | 2025 | 6 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2025 | 8 | 0.060 |
Why?
|
| Oligodendrocyte Precursor Cells | 1 | 2025 | 1 | 0.060 |
Why?
|
| Frail Elderly | 1 | 2025 | 3 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2025 | 4 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2025 | 5 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2025 | 17 | 0.060 |
Why?
|
| Fracture Fixation, Internal | 1 | 2025 | 4 | 0.060 |
Why?
|
| Drug Carriers | 1 | 2025 | 9 | 0.060 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2025 | 1 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2025 | 17 | 0.060 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2024 | 1 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2025 | 4 | 0.060 |
Why?
|
| Gastrointestinal Tract | 1 | 2025 | 5 | 0.060 |
Why?
|
| Ejaculation | 1 | 2024 | 1 | 0.060 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2024 | 1 | 0.060 |
Why?
|
| Semen Preservation | 1 | 2024 | 2 | 0.060 |
Why?
|
| Global Health | 1 | 2024 | 4 | 0.060 |
Why?
|
| Interferon Type I | 1 | 2024 | 1 | 0.060 |
Why?
|
| Metabolomics | 1 | 2025 | 6 | 0.060 |
Why?
|
| Survival Rate | 1 | 2024 | 16 | 0.060 |
Why?
|
| Breast Neoplasms, Male | 1 | 2024 | 3 | 0.060 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family | 1 | 2024 | 1 | 0.060 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2024 | 1 | 0.060 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2024 | 2 | 0.060 |
Why?
|
| Ultrasonic Waves | 1 | 2024 | 3 | 0.060 |
Why?
|
| Sonication | 1 | 2024 | 2 | 0.060 |
Why?
|
| Lycium | 1 | 2024 | 1 | 0.060 |
Why?
|
| Protein Folding | 1 | 2024 | 15 | 0.060 |
Why?
|
| Paraproteinemias | 1 | 2024 | 1 | 0.060 |
Why?
|
| Cost of Illness | 1 | 2024 | 6 | 0.060 |
Why?
|
| Purines | 1 | 2024 | 5 | 0.060 |
Why?
|
| Molecular Weight | 1 | 2024 | 7 | 0.060 |
Why?
|
| Loss of Function Mutation | 1 | 2024 | 2 | 0.060 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2024 | 8 | 0.060 |
Why?
|
| Interleukins | 1 | 2024 | 3 | 0.060 |
Why?
|
| Enterobacteriaceae | 1 | 2024 | 1 | 0.060 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 8 | 0.060 |
Why?
|
| Energy Metabolism | 1 | 2025 | 20 | 0.060 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2024 | 16 | 0.060 |
Why?
|
| Forests | 1 | 2024 | 1 | 0.060 |
Why?
|
| Aminopyridines | 1 | 2024 | 6 | 0.060 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2024 | 1 | 0.060 |
Why?
|
| Nasopharynx | 1 | 2024 | 1 | 0.060 |
Why?
|
| Water Supply | 1 | 2024 | 2 | 0.060 |
Why?
|
| Capsules | 1 | 2024 | 2 | 0.060 |
Why?
|
| Agriculture | 1 | 2024 | 6 | 0.060 |
Why?
|
| Ginsenosides | 1 | 2024 | 3 | 0.060 |
Why?
|
| Eye Diseases | 1 | 2025 | 17 | 0.060 |
Why?
|
| Immune System | 1 | 2024 | 12 | 0.060 |
Why?
|
| Grassland | 1 | 2024 | 7 | 0.060 |
Why?
|
| Solubility | 1 | 2024 | 11 | 0.060 |
Why?
|
| Influenza, Human | 1 | 2024 | 2 | 0.060 |
Why?
|
| Oocytes | 1 | 2024 | 2 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2024 | 18 | 0.060 |
Why?
|
| Cetuximab | 1 | 2024 | 1 | 0.060 |
Why?
|
| Bayes Theorem | 1 | 2024 | 26 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2024 | 49 | 0.060 |
Why?
|
| ErbB Receptors | 1 | 2024 | 6 | 0.060 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 2 | 0.060 |
Why?
|
| Carbapenems | 1 | 2024 | 8 | 0.060 |
Why?
|
| Tumor Escape | 1 | 2024 | 5 | 0.060 |
Why?
|
| Polyethylene Glycols | 1 | 2024 | 28 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2025 | 55 | 0.060 |
Why?
|
| Genome | 1 | 2024 | 22 | 0.060 |
Why?
|
| Recovery of Function | 1 | 2024 | 21 | 0.060 |
Why?
|
| DNA Fragmentation | 1 | 2024 | 2 | 0.060 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2024 | 2 | 0.060 |
Why?
|
| Gene Expression | 1 | 2025 | 52 | 0.060 |
Why?
|
| Myocardium | 1 | 2024 | 35 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2025 | 55 | 0.060 |
Why?
|
| Endothelial Cells | 1 | 2024 | 48 | 0.060 |
Why?
|
| Phenotype | 1 | 2024 | 73 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2024 | 11 | 0.060 |
Why?
|
| Tumor Burden | 1 | 2024 | 3 | 0.060 |
Why?
|
| Infant | 1 | 2024 | 87 | 0.060 |
Why?
|
| Pandemics | 1 | 2024 | 82 | 0.060 |
Why?
|
| Sleep | 1 | 2024 | 62 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2024 | 187 | 0.050 |
Why?
|
| Rats | 1 | 2024 | 251 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 284 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 277 | 0.050 |
Why?
|
| Child | 1 | 2024 | 657 | 0.050 |
Why?
|
| Brain | 1 | 2024 | 286 | 0.050 |
Why?
|